The global market for anti-inflammatory treatments is expected to reach over $106 billion in 2020. There are significant limitations with existing treatments and a real requirement for better and safer anti-inflammatory treatments for the many people affected by these serious conditions.
AD, the most common type or eczema, is a chronic, relapsing and debilitating inflammatory disease of the skin, very common in childhood but also affecting adolescents and adults.
Patients experience very dry, itchy skin that classically appears on their faces, inside their elbows and behind their knees but can affect any area of the body. Scratching leads to redness, swelling, cracking, “weeping” clear fluid, crusting and scaling. Often, the skin gets worse (flares), and then it improves or clears up (remissions).
It is very common, and increasingly common in industrialized countries. It affects up to 20% of infants and young children and 3% of adults; ~60% of young people continue with one or more symptoms into adulthood.
This is a multifactorial disease and its pathophysiology has been linked to genetic modification of skin barrier function, bacterial (e.g. Staphylococcus aureus) colonization and inflammation.
Over-the-counter (OTC) remedies and lubricants can help in symptom relief but do not tackle the underlying disease. Second-line treatments are topical corticosteroids with topical calcineurin inhibitors as a third-line option. These treatments are challenging for patients because of their significant side effects. There is a clear unmet medical need for safer, more effective treatments suitable for all age groups.
The US cost of treatment for AD is $12 billion per year, 75% are indirect costs (over-the-counter (OTC) remedies, lubricants, days lost from work) and the remainder are direct costs (physician visits, hospitalizations, medicines). The global market is valued at $6 billion.
IBD is a group of serious disorders that primarily includes ulcerative colitis (UC) and Crohn’s disease (CD). Both UC and CD are long-term (chronic) diseases involving inflammation of the gastrointestinal tract. UC only affects the colon (large intestine), while CD can affect the entire digestive system.
IBD can significantly affect daily living and lead to life-threatening complications. It is one of the most prevalent gastrointestinal diseases. Patients with IBD suffer from a range of uncomfortable and debilitating symptoms, including diarrhoea and abdominal pain. Complications can include perforation (rupture) of the bowl and patients with IBD may have an increased risk of developing bowel cancer.
Over 5 million people suffer from IBD worldwide, including 2.2 million in the EU and 1.6 million in the USA. Global prevalence is estimated at 396/100,000 population (UC: 0.5-24.5/100,00, CD: 0.1-16/100,000). The global market is valued at $9.6 billion.
Current treatments tend to be challenging for patients, both in terms of efficacy and side-effects, and there is a significant need for new, simple and safe medications that induce and maintain remission.
Carocell Bio’s focus is on developing treatments for UC. The aim of drug therapy in UC is essentially two-fold; firstly, to induce remission and secondly (and importantly) prevent subsequent relapses.
5-aminosalicylic acid (5-ASA) formulations are first-line therapy and are generally well tolerated and effective in inducing remission in some patients, particularly those with mild-to-moderate disease. However, a substantial proportion of patients need additional therapy to attain remission and many patients relapse despite chronic 5-ASA therapy.
In patients who ‘fail’ 5-ASA treatment, steroids and a range of biologics/small molecules are used to induce remission. However, these medications are far from ideal because they have substantial toxicity and are not effective in all patients.
There is a considerable market for new compounds that induce and maintain remission with a safety profile that supports chronic use. Carocell considers its portfolio to have considerable potential in this market, particularly as an additional therapy in mild-to-moderate UC patients.
If you would like to speak to us in detail about investing, tax benefits, donating or assisting us in any way at all, please contact us via the details below and we will get back to you as soon as possible.
UK: +44 (0) 20 3097 1979
US: +1 212 863 9902
Carocell Bio, Inc.
500 Delaware Avenue
©2018 Carocell Bio Ltd.
The BioHub at Alderley Park
Mereside, Alderley Park